Article Information
History
- August 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Mayu Nagura-Ikedaa,
- Kazuo Imaia,b,*,
- Katsumi Kubotac,
- Sakiko Noguchic,
- Yutaro Kitagawac,
- Masaru Matsuokac,
- Sakiko Tabataa,
- Kazuyasu Miyoshia,
- Toshimitsu Itoa,
- Kaku Tamuraa and
- Takuya Maedac
- aSelf-Defense Forces Central Hospital, Tokyo, Japan
- bDepartment of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan
- cDepartment of Clinical Laboratory, Saitama Medical University, Saitama, Japan
- ↵*Corresponding author:
Kazuo Imai, M.D., Self-Defense Forces Central Hospital, 24-2-1 Ikejiri, Setagaya-ku, Tokyo 154-0001, Japan, E-mail: k_imai{at}saitama-med.ac.jp, Tel: +81-3-3411-0151
Posted August 04, 2020.
Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan
